The FDA has lost no time in approving Vertex Pharma and CRISPR Therapeutics pioneering gene-editing therapy Casgevy for its second use, approving the drug for transfusion-dependent beta ...

Gene-editing therapy Casgevy has been approved for over a year in treating sickle cell disease and transfusion-dependent beta-thalassemia. Sure, it only generated revenue of $8 million in the ...

Vertex and CRISPR Therapeutics have won the backing of NICE for their gene-editing therapy Casgevy as a treatment for the blood disorder beta thalassaemia, a few months after turning it down for ...

Optum Rx, is the pharmacy benefit manager owned by UnitedHealth Group Inc’s UNH Also Read: HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is ...

Prosper Junior Bakiny (Eli Lilly): What's considered excellent revenue growth depends on the industry. For pharmaceutical companies, especially those with a market cap above $50 billion, year-over ...

Along with partner Vertex Pharmaceuticals, it has won regulatory approval for Casgevy, a revolutionary treatment for SCD and beta-thalassemia. Meanwhile, Intellia is partnered with Regeneron ...

The commercial launch of the first CRISPR-based gene therapy, Casgevy, is progressing well. Investing in stocks that aren't performing well can be a good move, but only if there are good reasons ...